Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Frequently asked questions
What sector does Shattuck Labs, Inc (STTK) operate in?
Shattuck Labs, Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Shattuck Labs, Inc (STTK) current stock price?
As of the latest data, Shattuck Labs, Inc stock price is $5.54, with a previous close of $5.49. Shattuck Labs, Inc gained $0.05 in the last trading session, representing a 0.91% increase.
What is Shattuck Labs, Inc (STTK) current market capitalization?
Shattuck Labs, Inc market cap is approximately 556.01 million.
What is Shattuck Labs, Inc (STTK) Earnings Per Share (EPS)?
The trailing EPS is -$0.44, and the forward EPS is -$0.52.
What is Shattuck Labs, Inc (STTK) EBITDA?
Shattuck Labs, Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -13.75 million.
Does Shattuck Labs, Inc (STTK) pay dividends?
No. Shattuck Labs, Inc does not pay a dividend.
When is Shattuck Labs, Inc (STTK) next earnings report?
Shattuck Labs, Inc is expected to release its next earnings report on September 30, 2026.
What is Shattuck Labs, Inc (STTK) beta (volatility) score?
Shattuck Labs, Inc has a beta of 1.100, meaning its volatility is roughly in line with the market.
